Mechanisms in blood-brain barrier opening and metabolism-challenged cerebrovascular ischemia with emphasis on ischemic stroke

S Sarvari, F Moakedi, E Hone, JW Simpkins… - Metabolic brain disease, 2020 - Springer
Stroke is the leading cause of disability among adults as well as the 2nd leading cause of
death globally. Ischemic stroke accounts for about 85% of strokes, and currently, tissue …

Current drug treatment of acute ischemic stroke: challenges and opportunities

DF Muresanu, S Strilciuc, A Stan - CNS drugs, 2019 - Springer
Patient-level health outcomes for acute ischemic stroke have significantly improved in the
last decade primarily because of superior overall case management, availability of tailored …

Neuroprotective effect of magnesium supplementation on cerebral ischemic diseases

R Xu, L Wang, L Sun, J Dong - Life Sciences, 2021 - Elsevier
Ischemic encephalopathy is associated with a high mortality and rate of disability. The most
common type of ischemic encephalopathy, ischemic stroke, is the second leading cause of …

ADAMTS13: an emerging target in stroke therapy

X Chen, X Cheng, S Zhang, D Wu - Frontiers in neurology, 2019 - frontiersin.org
Thrombosis is the predominant underlying mechanism of acute ischemic stroke (AIS).
Though thrombolysis with tPA has been proven to be effective in treating AIS within the time …

Comparison of thrombolytic agents in treatment of patients with acute ischemic stroke; findings from a single centre follow up study in real-life settings.

M George, N Baby, R Paul, M Zabeer… - Journal of Clinical …, 2021 - Elsevier
Background and objectives Health outcome data of thrombolysis in patients with acute
ischemic stroke in real life-settings in India are scarce. We studied the clinical profile, risk …

Adapting clinical practice of thrombolysis for acute ischemic stroke beyond 4.5 hours: a review of the literature

AN Simpkins, P Tahsili-Fahadan, N Buchwald… - Journal of Stroke and …, 2021 - Elsevier
Several clinical trials have demonstrated that advanced neuroimaging can select patients for
recanalization therapy in an extended time window. The favorable functional outcomes and …

Biosimilar tenecteplase versus alteplase in acute ischemic stroke: A real world study

A Mohan, S Komakula, S Murali, P Anand… - Annals of Indian …, 2023 - journals.lww.com
Background and Purpose: There is an unmet need for a more effective thrombolytic agent in
acute ischemic stroke (AIS) management. Various studies and meta-analysis suggest …

Essential workflow and performance measures for optimizing acute ischemic stroke treatment in India

MVP Srivastava, R Bhatia, VY Vishnu, M Goyal - Stroke, 2020 - Am Heart Assoc
Stroke is a leading cause of death in India, which has one-fifth of the world's population. The
approximate age-adjusted prevalence of stroke in India is 84 to 262/100 000 in rural and …

Minocycline exhibits synergism with conditioned medium of bone marrow mesenchymal stem cells against ischemic stroke

MJ Tsai, DY Liou, YC Chu, Y Chen… - Journal of Tissue …, 2021 - Wiley Online Library
Several lines of evidence show that a conditioned medium of bone marrow mesenchymal
stem cells (BM‐MSCcm) improve functional recovery after ischemic stroke but do not reduce …

Tenecteplase versus alteplase (TENVALT): A study comparing two thrombolytic agents in acute ischemic stroke.

K Sundar, L Bhirud, A Panwar, JJ Cherian… - Neurology …, 2019 - search.ebscohost.com
Abstract Background & Objective: The Indian data comparing the efficacy and safety
outcomes of tenecteplase and alteplase in acute ischemic stroke is scarce. We aimed to …